ESSA Pharma Announces Initiation Of Phase 2 Study Evaluating Masofaniten (EPI-7386) In Combination with Enzalutamide In Patients with Metastatic Castration-Resistant Prostate Cancer
Portfolio Pulse from Benzinga Newsdesk
ESSA Pharma has announced the initiation of a Phase 2 study evaluating Masofaniten (EPI-7386) in combination with Enzalutamide in patients with metastatic castration-resistant prostate cancer.
September 18, 2023 | 11:02 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The initiation of the Phase 2 study by ESSA Pharma could potentially lead to positive outcomes for the company if the study yields successful results.
The initiation of a Phase 2 study is a significant step in the development of a new drug. If the study yields positive results, it could potentially lead to the drug's approval and commercialization, which would be beneficial for ESSA Pharma's financial performance and stock price.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100